Plandaí Biotechnology (OTCPK:PLPL), "headquartered" in Seattle, is seeking to "transform the world of nutraceuticals" by growing green tea in South Africa and employing specialized extraction technologies in order to produce a highly bioavailable green tea gallate catechin. The company believes that it can potentially cure malaria, and it also suggests that its "Phytofare Catechin Complex" may lead to weight loss among many other possible positive health indications, like curing cancer or HIV. While these are significant opportunities to address large problems that have led investors to drive PLPL up over 1000% in 2013, a careful review of the company's background and financials reveals many red flags that suggest investors are at risk of losing their entire investment. With...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|